Galderma Says Long-Term Data On Nemluvio (Nemolizumab) Demonstrate Its Favorable Safety Profile

Published on 06/06/2025 at 01:02

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Galderma Group AG

Galderma's Sculptra-Restylane Regimen Sustains Facial Aesthetic Improvement in Phase 4 Study	Jul. 17	MT
RBC Lifts Galderma Price Target Amid Expectations of 'Good' H1	Jul. 17	MT
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction with Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss	Jul. 17	CI
William O'Neil & Co. Restarts Galderma Coverage at Buy	Jul. 09	MT
Swiss Equities in the Green; Galderma Gains	Jul. 08	MT
Barclays Kicks Off Galderma Coverage at Overweight	Jul. 08	MT
Galderma's Finance Chief to Leave	Jul. 01	MT
Galderma Group AG Announces Departure of Thomas Dittrich as Chief Financial Officer	Jul. 01	CI
Swiss Market Index Retreats; Galderma Shares Rise	Jun. 25	MT
Galderma Initiates Phase 2 Trials to Evaluate Systemic Sclerosis, Chronic Pruritus Treatment	Jun. 25	MT
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients with Systemic Sclerosis and Chronic Pruritus of unknown Origin	Jun. 25	CI
Galderma Group AG(SWX:GALD) added to S&P International 700	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P EUROPE 350 - Health Care	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P EUROPE 350	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P Global 1200	Jun. 22	CI
Galderma Announces Data from New Interim Analysis of Study Investigating the Long-Term Safety and Efficacy of Nemluvio in Moderate-To-Severe Prurigo Nodularis	Jun. 18	CI
Galderma Group AG - New Data Demonstrate Nemluvio®'S (Nemolizumab) Favorable Safety Profile	Jun. 18	RE
Galderma Publishes New Data On Nemluvio's Safety Profile	Jun. 18	RE
Swiss stocks - Factors to watch on June 18	Jun. 18	RE
Galderma Establishes New U.S. Headquarters In Miami	Jun. 17	RE
Galderma Establishes New U.S. Headquarters in Miami and Strengthens Regional Leadership	Jun. 17	CI
Galderma?S Nemluvio® (Nemolizumab) Receives National Institute for Health and Care Excellence Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales	Jun. 12	CI
Galderma's Atopic Dermatitis Drug Gets Backing for Routine NHS Funding	Jun. 12	MT
Galderma Announces Two-Year Data from A New Interim Analysis of A Long-Term Extension Study Investigating the Safety and Efficacy of Nemluvio in Moderate-To-Severe Atopic Dermatitis	Jun. 06	CI